Bank Of The Ozarks buys $2,621,283 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Bank Of The Ozarks scooped up 7,845 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 39,013 shares of AbbVie Inc which is valued at $2,621,283.AbbVie Inc makes up approximately 0.95% of Bank Of The Ozarks’s portfolio.

Other Hedge Funds, Including , Summit Securities Group boosted its stake in ABBV in the latest quarter, The investment management firm added 1,964 additional shares and now holds a total of 5,948 shares of AbbVie Inc which is valued at $399,646. AbbVie Inc makes up approx 0.21% of Summit Securities Group’s portfolio.Zwj Investment Counsel Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 1,150 additional shares and now holds a total of 35,344 shares of AbbVie Inc which is valued at $2,366,281. AbbVie Inc makes up approx 0.24% of Zwj Investment Counsel Inc’s portfolio.Interocean Capital reduced its stake in ABBV by selling 1,585 shares or 25.31% in the most recent quarter. The Hedge Fund company now holds 4,678 shares of ABBV which is valued at $311,274. AbbVie Inc makes up approx 0.07% of Interocean Capital’s portfolio. Achievement Holdings sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 5,100 shares of ABBV which is valued $330,990.

AbbVie Inc closed down -0.1 points or -0.15% at $64.51 with 50,99,249 shares getting traded on Monday. Post opening the session at $64.84, the shares hit an intraday low of $64.19 and an intraday high of $65.09 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.